IRCT20180618040127N1Not yet recruitingPhase 3
Evaluation of the therapeutic effect of Gluronic acid in HTLV-1 patients and its effect on viral and inflammatory factors
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- no limit to no limit (—)
- Sex
- All
Inclusion Criteria
- •HTLV-1 positive serology
- •Symptoms of spastic paraparesis
- •Presence of anti-HTLV-1 antibody in the cerebrospinal fluid
- •MDG less than 9
- •Passing less than 15 years from incidence of disease symptoms
- •Patient informed consent to participate in the study
Exclusion Criteria
- •Other causes of spastic paraparesis
- •receive other drugs that affect the immune system
- •Existence of other diseases other than HAM / TSP
Investigators
Similar Trials
Not yet recruiting
Phase 3
Evaluation of efficacy and safety of Glurunic acid (G2013) in patients with COVID-19COVID-19.Covid-19U07.1IRCT20080901001165N64Ministry of Defense, Department of Health180
Recruiting
Phase 2
An exploratory study for therapeutic effects of geranylgeranylacetone on heart failureheart failureJPRN-jRCTs031220395Akasaka Takeshi160
Recruiting
Phase 2
Therapeutic effect of Guluronat on disease severity in MSMultiple Sclerosis.Multiple SclerosisIRCT2017042313739N8Vice chancellor for Research, Tehran University of Medical Sciences50
Not yet recruiting
Phase 4
Effect of application of Glutathione with Vitamin c gel and Glutathione Gel alone after Gingival depigmentation surgeryCTRI/2024/07/069885DrKhushee Agrawal
Not yet recruiting
Not Applicable
The relationship between therapeutic effects of gulucocorticoid pulse and lymphcytic surface markers in Graves' ophthalmopathy.graves'ophthalmopathyJPRN-UMIN000013854Tottori University, Faculty of Medicine30